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The resistance of Aspergillus species to antifungal is increasingly reported and the knowledge of the local
epidemiology and antifungal susceptibility pattern is pivotal to define adequate treatment policies. Our study aimed
to: 1) describe the in vitro antifungal susceptibility profile of the Aspergillus species isolated from patients with
haematological malignancies in Tunisia; 2) compare the E-test and Sensititre Yeast-One assays for the detection of
paradoxical growth and trailing effect, both phenotypes commonly exhibited by Aspergillus spp. upon exposure to
caspofungin and 3) to evaluate the mortality rate in patients according to the causative Aspergillus species and the
antifungal treatment.
We tested amphotericin B, itraconazole, voriconazole, posaconazole and caspofungin against 48 Aspergillus isolates
(17, A. niger; 18, A. flavus; 9, A. tubingensis; 1, A. westerdijkiae; and 1, A. ochraceus) with the E-test. Minimal inhibition
concentrations were above the epidemiological cut-off values for amphotericin B in 67% of A. flavus strains; for
caspofungin in 22% of A. flavus strains; and for itraconazole in 22% of A. tubingensis strains, voriconazole and
posaconazole MICs were below the epidemiological cut-off values for all strains.
When exposed to caspofungin, 42% of the strains exhibited trailing effect and 38% paradoxical growth. Trailing
effect occurred in 61% of A. flavus strains and paradoxical growth in 62% of Aspergillus section Nigri strains. E-test
and Sensititre Yeast-One assays were only fairly concordant for the detection of these phenotypes. Repeatability of
both assays was high for trailing effect but poor for paradoxical growth. The relatively high frequency of
amphotericin B resistant strains makes voriconazole best adapted as a first-line treatment of invasive aspergillosis
from amphotericin B to voriconazole in this hospital.
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Invasive aspergillosis (IA) is a life threatening infection,
especially in neutropenic patients where it is associated
with a high mortality rate (Montagna et al., 2012; Blot
et al., 2012). Over the last two decades, new antifungal
agents including azoles and caspofungin were developed
in order to improve the prognosis of IA. In parallel, tests
for Aspergillus spp. in vitro antifungal susceptibility test-
ing were developed and commercialized (Pfaller, 2012).
The extensive use of antifungal agents was associated
with the emergence of azole-resistant Aspergillus spp.,
and caspofungin (CS) has been recommended as a sal-
vage treatment of IA (Pfaller et al., 2008; Jarque et al.,
2013). Thus, the in vitro susceptibility testing of Asper-
gillus spp. clinical strains to antifungal agents is required
both for driving and monitoring antifungal therapy and
for the global surveillance of Aspergillus spp. susceptibil-
ity (Rex and Pfaller, 2002). In vitro susceptibility tests are
based on the measurement of the fungal growth in the
presence of different drug concentrations so as to deter-
mine the minimum inhibitory concentration (MIC) of
antifungals (Wanger, 2012). Epidemiologic cut-off values
(ECVs) of the MIC were established for different Asper-
gillus species and different antifungal agents, in order to
assess the emergence of strains with decreased suscepti-
bility (Espinel-Ingroff et al., 2011a, Espinel-Ingroff et al.
2011b). A wild type organism being defined as a strain
which does not harbor any acquired resistance to the
particular antimicrobial agent being examined (Pfaller
et al., 2011).
When exposed to CS, in addition to the clear end
point phenotype (defined as the absence of growth at
concentrations above the MIC), Aspergillus spp. exhibit
two unusual in vitro testing phenotypes that are referred
to as trailing effect (TE) and paradoxical growth (PG).
TE is characterized by a reduced but persistent growth
at concentrations above the MIC. PG is characterized by
growth in the presence of low concentrations, no growth
at intermediate concentrations, and growth resuming at
higher concentrations (Fortwendel et al., 2010).
The aims of our study were to evaluate the in vitro an-
tifungal susceptibility profile of Aspergillus spp. strains
isolated from patients with haematological malignanciesTable 1 Epidemiological cut-off values for amphotericin, itrac
according to the Aspergillus species
Species AMBa (mg/l) ITRb (mg
A. niger 4 2
A. flavus 4 1
A. fumigatus 4 1
A. tubingensis 4 2
Aspergillus section Circumdati 4 1
aamphotericin; bitraconazole; cvoriconazole; dposaconazole; ecaspofungin.by using the E-test method, to assess both E-test™ and
Sensititre Yeast-One™ (SYO) assays for the detection of
PG and TE phenotypes exhibited by Aspergillus spp.
upon exposure to CS and to evaluate the mortality rate
in patients according to the causative Aspergillus species
and the antifungal treatment.
Material and methods
Isolates
We tested 48 clinical Aspergillus isolates, including 17
A. niger, 18 A. flavus, 9 A. tubingensis, 2 A. fumigatus, 1
A. westerdijkiae and 1 A. ochraceus. These isolates were
recovered from the sputa of 30 patients treated for acute
leukaemia in the haematology unit of the Farhat Hached
hospital of Sousse (central Tunisia). The sputa were in-
oculated onto Sabouraud-chloramphenicol medium and
plates were incubated at 25 and 35°C. Aspergillus sec-
tions were identified on the basis of macroscopic and
microscopic characteristics of the colonies (De Hoog
et al., 2000), whereas the identification at the species
level was performed by using both Matrix-Assisted Laser
Desorption Ionization Time-Of-Flight (MALDI-TOF)
mass spectrometry on a Microflex LT™ (Bruker Daltonics,
Germany) instrument (Cassagne et al., 2012) and DNA se-
quencing of the ITS1-5.8-ITS2 and the 28S unit D1-D2
regions of the rRNA gene, and the partial beta-tubulin
(BTUB) gene (Hendrickx et al., 2012).
Antifungal susceptibility testing
We assessed the susceptibility of all the 48 isolates to
the five following antifungal agents: amphotericin B
(AMB), itraconazole (ITR), voriconazole (VOR), posaco-
nazole (POS) and caspofungin (CS) by using the E-test
(bioMérieux, France) assay with RPMI medium (AES,
France) according to the supplier’s recommendations.
The plates were incubated at 30°C for 48 hours. The
MIC was determined at 100% inhibition for all tested
antifungals and red at the lowest drug concentration at
which the border of the elliptical inhibition intercepted
the scale of the antifungal strip.
For each antifungal, we used the previously described
ECVs, detailed in the Table 1, to detect the isolates within
each species that might have acquired a mutationalonazole, voriconazole, posaconazole and caspofungin
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et al., 2011a, Espinel-Ingroff et al. 2011b; Pfaller et al.,
2011). Because ECVs had not been established for A. tubin-
gensis (section Nigri) and for the Circumdati section, we
used A. niger’s ECVs for A. tubingensis and those of
A. fumigatus for species of section Circumdati.
We assessed both E-test and SYO (Trek Diagnostic Sys-
tems, Ltd., United Kingdom) assays for the detection of PG
and TE phenotypes exhibited by Aspergillus spp. upon ex-
posure to CS. Therefore, we analysed the CS in vitro phe-
notypes of 10 randomly selected isolates (4 A. niger, 4
A. flavus and 2 A. tubingensis) for which both E-test and
SYO assays were performed in triplicate. The SYO was per-
formed according the supplier’s recommendations. Briefly,Table 2 MIC range, MIC50 and MIC90 of the 48 clinical Asperg
Species Antifungal agent






























aamphotericin; bitraconazole; cvoriconazole; dposaconazole; ecaspofungin; fepidemiothe inoculum suspension was prepared from a 72 hours
culture grown on Sabouraud dextrose agar and adjusted to
the density of a 0.5 McFarland standard. The plates were
incubated at 30°C and red at 24 and 48 hours by visual in-
spection. The MIC value corresponds to the first well that
shows a change in colour from pink to purple (indicating
inhibition of growth). ATCC 22019 and ATCC 6258 were
used as quality control strains.
Data analysis
MICs data of the E-test assay were presented as the
MIC range, MIC50, and MIC90 for each species. The
inter-assay concordance was estimated via Cohen’s
kappa coefficient, by considering triplicate assays resultsillus isolates
MIC (mg/l)
Range MIC50 MIC90 % > ECV
f
0.04–1.5 0.44 0.75 0
0.38–2 0.98 2 0
0.05–0.12 0.1 0.13 0
0.05–0.25 0.12 0.25 0
0.008–0.12 0.03 0.07 0
0.5–0.32 6 20.8 66.6
0.25–1 0.5 0.83 0
0.06–0.5 0.19 0.25 0
0.06–0.25 0.19 0.25 0
0.004–32 0.064 32 22.2
0.09–0.5 0.24 0.4 0
0.25–8 0.19 4.8 22.2
0.064–0.38 0.13 0.38 0
0.047–0.25 0.12 0.25 0
0.008–0.012 0.01 0.012 0
3–6 NRg NR NR
0.8–0.5 NR NR NR
0.06–0.13 NR NR NR
0.06–0.13 NR NR NR
0.06–0.06 0.064 NR NR
3–24 NR NR NR
0.38–1 NR NR NR
0.04–0.06 NR NR NR
0.09–0.25 NR NR NR
0.023–0.13 NR NR NR
0.04–32 0.63 13.2 25
0.25–8 0.5 2 4.1
0.04–0.5 0.13 0.25 0
0.05–0.25 0.13 0.25 0
0.004–32 0.023 0.125 8.3
logic cut-off value; gnot relevant.
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match [<0], poor agreement [0–0.2], fair agreement
[0.21-0.4], moderate agreement [0.41-0.6], good agree-
ment [0.61-0.8], very good agreement [0.81-1]. Logistic
regression analysis was performed to calculate the risk
of a patient’s fatal outcome associated with the first-line
antifungal treatment. All statistical analyses were per-
formed using SAS, version 9.2 (SAS Institute, Cary, NC).
This study was approved by the Comité d’Ethique et




The MIC data are shown in Table 2. The MIC50 of all
investigated antifungals for all Aspergillus species were
low, indicating the absence of natural antifungal resist-
ance of the tested species. When MIC90 are considered,
AMB and ITR showed high values as compared to the
remaining antifungals; thus indicating that some isolates
had developed resistance to AMB and ITR.
The MIC50 and MIC90 of AMB were 0.63 and 13.2 mg/l,
respectively, for all species. The MIC90 of AMB was much
lower for both A. tubingensis (0.75 mg/l) and A. niger
(0.4 mg/l) than for A. flavus (20.8 mg/l). Twelve (66.6%)
A. flavus isolates had AMB MIC above the corresponding
ECV, indicating that these isolates have acquired aFigure 1 Caspofungin in vitro testing phenotypes of Aspergillus spp. w
the E-test (bioMérieux) assays. Clear end point (A. tubingensis, panel A1,
panel B2, E-test) and Trailing effect (A. flavus, panel C1, SYO; panel C2, E-teresistance to AMB. All the 36 remaining investigated
strains were susceptible to AMB.
The MIC50 and MIC90 of ITR were 0.5 and 2 mg/l,
respectively, for all species. Only the black Aspergillus
species had relatively high ITR MIC90: 2 mg/l for
A. niger and 4.8 mg/l for A. tubingensis. Two (22%)
A. tubingensis isolates had ITR MIC > ECV. The MIC of
CS were > ECV in only 4 (22%) A. flavus isolates. The
MIC of VOR and POS were below the ECVs in all the
48 tested isolates.
Caspofungin in vitro susceptibility testing phenotypes
In order to estimate the frequency of the different pheno-
types exhibited by Aspergillus upon in vitro CS exposure,
we considered the results of the E-test susceptibility pro-
files. The CS in vitro testing phenotypes are illustrated in
Figure 1. Out of the 48 tested Aspergillus isolates, 10 (21%)
exhibited a clear end point, 20 (42%) TE and 18 (38%) PG
(Table 3). TE was more frequent with A. flavus (61%) and
PG was only observed with the Aspergillus section Nigri
(A. niger and A. tubingensis) isolates (61.5%). The mean CS
concentration at which Aspergillus isolates growth resumed
was 0.19 ± 0.15 mg/l.
We further compared the repeatability of the different CS
phenotypes with both E-test and SYO assays and estimated
the inter-assay concordance. PG never occurred simultan-
eously with both E-test and SYO. The TE phenotype wasith the Sensititre Yeast-One (SYO, Trek Diagnostic Systems) and
SYO; panel A2, E-test), Paradoxical growth (A. niger, panel B1, SYO;
st).
Table 3 Caspofungin E-test susceptibility testing phenotypes in 48 Aspergillus isolates
Clear end point Trailing effect Paradoxical growth
A. niger (n = 17) 1 (6%) 4 (23.5%) 12 (70.5%)
A. tubingensis (n = 9) 4 (44.5%) 1 (11%) 4 (44.5%)
A. flavus (n = 18) 5 (28%) 11 (61%) 2 (11%)
A. fumigatus (n = 2) 0 2 (100%) 0
A. ochraceus (n = 1) 0 1 (100%) 0
A. westerdijkiae (n = 1) 0 1 (100%) 0
All species (n = 48) 10 (21%) 20 (42%) 18 (38%)
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E-test was used, whereas PG phenotype was poorly repeat-
able using both assays (Table 4). E-test and SYO assays
were fairly concordant with 0.35 and 0.26 kappa values for
TE and PG, respectively.Mortality rate according to the Aspergillus species and
antifungal treatment
Among the specimens obtained from the 18 patients who
died, species of section Nigri were isolated from 10 (55.5%)
sputa, species of section Flavi from 6 (33.3%) sputa and
other Aspergillus species from 2 (11.1%) sputa (Table 5).
The association of Aspergillus species with a fatal outcome
was not statistically significant (p = 0.81). Among the pa-
tients with a fatal outcome, seven had been treated with
AMB, two with VOR and nine received no antifungal treat-
ment. The first-line antifungal treatment was statistically
significantly (p = 0.02) associated with the patients’ out-
come. Logistic regression analysis indicated that the risk of
death was increased in the patients treated with AMB
(OR = 3.89, 95% CI [0.80 to 18.98], p = 0.0144) and de-
creased in the patients treated with VOR (OR = 0.28,
95% CI [0.50 to 1.54], p = 0.0233) when compared to those
who were not treated by antifungals.Table 4 Repeatability of triplicate caspofungin E-test and SYO
Isolate Species E-test
Clear end point Trailing effect Paradoxic
1 A. niger 0 2 1
2 A. niger 0 2 1
3 A. niger 0 0 3
4 A. niger 1 1 1
5 A. tubingensis 1 1 1
6 A. tubingensis 1 1 1
7 A. flavus 0 3 0
8 A. flavus 0 3 0
9 A. flavus 0 3 0
10 A. flavus 1 2 0Discussion
Our study revealed that Aspergillus of sections Nigri and
Flavi were the most frequently isolated species from our
patients’ airways samples. This reflects the particular As-
pergillus species spectrum involved in IA in Tunisia that
contrasts with the prevalent data from developed
Northern countries where Aspergillus section Fumigati
is responsible for more than 80% of IA cases, followed
by the section Flavi (10%); the sections Nigri, Nidulantes
and Terrei causing the remaining 10% of cases (Krishnan
et al., 2009; Wald et al., 1997). This finding may be ex-
plained by the qualitative and quantitative variations in
environmental Aspergillus flora according to local cli-
mate and points out the need for in vitro susceptibility
testing of clinical strains in order to select the appropri-
ate predictive therapy.
All the tested strains of sections Nigri, Fumigati and
Circumdati were susceptible to AMB with MIC90 < ECV.
This finding is in accordance with the results of other
studies where no AMB resistance was reported in iso-
lates of the section Nigri (Hadrich et al., 2012a). Espinel-
Ingroff et al. showed that there were no MIC above the
ECV for A. niger (Espinel-Ingroff et al., 2011a). Similarly
low AMB MIC (MIC mostly <0.5 mg/l) have been re-
cently reported by Alcazar-Fuoli et al. and Baddley et al.in vitro susceptibility testing results
SYO











Table 5 Univariate analysis of the patients’ outcome
according to the Aspergillus species and antifungal
treatment
Death Survival P
Aspergillus section Flavi 6 (33%) 12 (40%) 0.81
Aspergillus section Nigri 10 (56%) 16 (53%)
Other Aspergillus spp. 2 (11%) 2 (11%)
Treatment AMB 7 (39%) 3 (10%) 0.02
VOR 2 (11%) 12 (40%)
No 9 (50%) 15 (50%)
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2009).
In contrast, 66.6% of A. flavus isolates exceeded AMB’s
ECV. This finding is in line with Hadrich et al., who
showed that 84% of A. flavus strains isolated in Sfax, a
city located south of Tunisia, had a reduced susceptibil-
ity to AMB (Hadrich et al., 2012b). It is also in accord-
ance with those reported by Lass-Flörl et al. who
showed that 67% of A. flavus isolates in Austria were re-
sistant to AMB and that this in vitro resistance was asso-
ciated with AMB therapy failure (Lass-Flörl et al., 1998).
AMB resistance in A. flavus was of major concern be-
cause AMB deoxycholate was the first-line treatment of
IA in our hospital at the time of the study.
ITR was found to be active on all tested Aspergillus spe-
cies except for A. niger and A. tubingensis. A. niger showed
a reduced susceptibility to ITR. The recently described
A. tubingensis species was associated with higher ITR MICs
as compared to A. niger (4.8 mg/l vs 2 mg/l) and MIC
above ECV in 22% of isolates. The lower susceptibility of
A. tubingensis strains might be related to the occurrence of
a mutation, similarly to the one described by Howard et al.
at position 97 in the CYP51A gene of A. awamori, another
species of the section Nigri (Howard et al., 2011). The clin-
ical impact of in vitro resistance to ITR of Aspergillus iso-
lates is relatively modest because, especially in haematology
patients, this antifungal agent is used for prophylaxis rather
than for the curative treatment of IA (Döring et al., 2013).
With respect to VOR, neither resistance nor reduced
susceptibility could be demonstrated in any of the strains
tested. Our results contrast with those of Hendrickx
et al. who reported higher MICs to both VOR and ITR
in A. tubingensis (Hendrickx et al., 2012).
All strains were susceptible to POS, the MICs of which
being as low as those of VOR. Our results contrast with
those reported by Pfaller et al. who assessed the triazole
ECVs of 1789 Aspergillus isolates and showed that the
percentages of isolates for which MICs were greater than
the ECVs ranged from 1.1 to 5.7% for POS, 0.0 to 1.6%
for VRC and 0.7 to 4.0% for ITC (Pfaller et al., 2011).
More than 20% of A. flavus strains were resistant to CS.
This finding contrasts with the one in all other Aspergillusspecies that were susceptible, with very low MICs, to CS.
This relatively high resistance rate in A. flavus makes CS
poorly adapted to the treatment of IA in the local hospital
epidemiology setting. In contrast to our findings, Al-
Wathiqi et al. showed that the MIC90 of A. flavus was
0.032 mg/l and MIC was above the ECV in 6% of A. flavus
strains (Al-Wathiqi et al., 2013).
With respect to the Aspergillus species isolated from
our patients’ samples, the low susceptibility of a signifi-
cant proportion of strains to AMB and their high sus-
ceptibility to VOR, argue for the use of VOR as the first-
line treatment of IA in our hospital, especially in the
haematology unit. This is in line with the international
recommendations (Seyedmousavi et al., 2013; Walsh
et al., 2008).
By analysing the particular CS in vitro testing phenotypes,
we concluded that TE and PG are not only dependent
on the Aspergillus species, but also on the strain and the
assay’s characteristics (Fortwendel et al., 2010). These dis-
tinct phenotypic responses to increasing CS concentrations
might result from differences in the genetic background of
Aspergillus species. Our study is the first to report the low
level of agreement between E-test and SYO and the rela-
tively poor reproducibility of both tests in the detection of
TE or PG in Aspergillus spp. These findings argue against a
simple genetic effect, and are more concordant with the
hypothesis that the mechanism could be a compensatory
up-regulation of the cell wall components’ synthesis, in
response to high CS concentrations which stimulate chitin
production (Fortwendel et al., 2010). Furthermore, the clin-
ical relevance of the capacity of fungal subpopulations to
survive and proliferate at high CS concentrations is debat-
able. Although the clinical significance of PG in fungi ex-
posed to CS remains unclear, we were concerned by the
fact that the concentration at which Aspergillus spp. growth
resumed was clearly below the expected 1 mg/l plasma
concentration in treated patients. Therefore, we suggest
that CS would benefit of being combined with another anti-
fungal in order to remove the PG effect (Gellen-Dautremer
et al., 2010).
When the causative Aspergillus species was considered,
the case fatality rate was similar between our patients. In
contrast, a significant association between the outcome of
the patients and the antifungal treatment was demon-
strated. This association should however be cautiously
interpreted, mainly because the treatments were not ran-
domly allocated. The fact that VOR was associated with a
better outcome is in agree with the current recommenda-
tions to using VOR as the first-line treatment of IA (Walsh
et al., 2008). The higher case fatality rate in the patients
who were treated with AMB as compared to those who did
not receive any antifungal treatment might result from the
drug’s toxicity or from a more severe form of IA disease in
treated patients. Furthermore, it is well known that the
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fungal susceptibility profile, but also on host factors, includ-
ing underlying disease, cellular and humoral immune
functions and antifungal agent’s pharmacokinetic/pharma-
codynamic properties; all these factors are considered to
play a critical role in the patients’ response to the treatment
(Steinbach et al., 2003).
Conclusions
Aspergillus of the section Nigri and Flavi were the most
frequently involved in IA in our patients with acute leu-
kaemia. More than 2/3 of A. flavus isolates showed a re-
duced susceptibility to AMB, and 22% of A. tubingensis
showed a reduced susceptibility to ITR. Based on these
findings, we recommend VOR for the first-line treat-
ment of IA in this haematology unit. The relatively poor
reproducibility of CS in vitro testing results suggests that
it cannot reliably be used to predict the patients’ out-
come. Further studies aiming at determining the clinical
significance of both TE and PG in vitro phenotypes are
warranted, mainly because when they occur, Aspergillus
spp. show the capacity to grow at concentrations clearly
below the expected plasma drug concentration in treated
patients.
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